Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Application of annotation-agnostic RNA sequencing data analysis tools for biomarker discovery in liquid biopsy.

ABSTRACT: Application of annotation-agnostic RNA sequencing data analysis tools for biomarker discovery in liquid biopsy.

PROVIDER: PRJNA762369 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15846115.fastq.gz	Fastqsanger.gz
	SRR15846116.fastq.gz	Fastqsanger.gz
	SRR15846117.fastq.gz	Fastqsanger.gz
	SRR15846118.fastq.gz	Fastqsanger.gz
	SRR15846119.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

Application of annotation-agnostic RNA sequencing data analysis tools for biomarker discovery in liquid biopsy.

Project description:We demonstrate an agnostic method to identify transcribed fragments from small Rna-Seq data using ALS patients and healthy donorâ€™s plasma.

2022-09-22 | GSE183942 | GEO

Application of annotation-agnostic RNA sequencing data analysis tools for biomarker discovery in liquid biopsy.

Project description:RNA sequencing analysis is an important field in the study of extracellular vesicles (EVs), as these particles contain a variety of RNA species that may have diagnostic, prognostic and predictive value. Many of the bioinformatics tools currently used to analyze EV cargo rely on third-party annotations. Recently, analysis of unannotated expressed RNAs has become of interest, since these may provide complementary information to traditional annotated biomarkers or may help refine biological signatures used in machine learning by including unknown regions. Here we perform a comparative analysis of annotation-free and classical read-summarization tools for the analysis of RNA sequencing data generated for EVs isolated from persons with amyotrophic lateral sclerosis (ALS) and healthy donors. Differential expression analysis and digital-droplet PCR validation of unannotated RNAs also confirmed their existence and demonstrates the usefulness of including such potential biomarkers in transcriptome analysis. We show that find-then-annotate methods perform similarly to standard tools for the analysis of known features, and can also identify unannotated expressed RNAs, two of which were validated as overexpressed in ALS samples. We demonstrate that these tools can therefore be used for a stand-alone analysis or easily integrated into current workflows and may be useful for re-analysis as annotations can be integrated post hoc.

| S-EPMC10213969 | biostudies-literature

Multi-parametric liquid biopsy approach

Project description:Multi-parametric liquid biopsy approach

| PRJEB39331 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887892 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887893 | ENA

Diagnostic accuracy of liquid biopsy in endometrial cancer

Project description:Diagnostic accuracy of liquid biopsy in endometrial cancer

| PRJNA767010 | ENA

Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer

Project description:Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions. The CMx platform has been showed to be able to the detection of Circulating Tumor Cells (CTCs) in high sensitivity and specificity. In published studies, circulating Tumor Cells (CTCs) are captured and quantified in advanced-stages of colorectal cancer. In order to detect early and pre-cancer circulating tumor cells, we have developed an Automated Liquid Biopsy Platform that improves the detection of CTCs in early cancer stages. Therefore, this study goals are: 1) to establish a standard detection process utilizing the Automated Liquid Biopsy Platform. 2) Parallel comparison of laboratory manual operation and Automated Liquid Biopsy Platform. 3) Verify the feasibility of use of an Automated Liquid Biopsy Platform in the clinical setting.

| 2269165 | ecrin-mdr-crc

Pre-analytical factors affecting the establishment of a single tube assay for multi-parameter liquid biopsy detection in melanoma patients

Project description:NGS liquid biopsy sequencing of miRNAs in total plasma and EV-associated miRNAs

2020-03-10 | GSE143231 | GEO

Application of ctDNA methylated liquid biopsy in the screening of postoperative recurrence of colorectal cancer with liver metastasis and evaluation of adjuvant therapy

Project description:Interventions: Gold Standard:Clinical outcome;Index test:ctDNA methylated liquid biopsy Primary outcome(s): ctDNA Study Design: Sequential

| 2697935 | ecrin-mdr-crc

Early Detection of Colorectal Cancer Using Liquid Biopsy

Project description:Primary outcome(s): Diagnostic accuracy of colorectal cancer by liquid biopsy Study Design: Observational Study Model : Case-control, Time Perspective : Cross-sectional, Enrollment : 500, Biospecimen Retention : Collect & Archive- Sample with DNA, Biospecimen Description : Whole blood, colon tissue

| 2514159 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data